Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A celastrol derivative-based multifunctional nanozyme for oxidative stress scavenging and lipid metabolism regulation in metabolic dysfunction-associated steatotic liver disease.

Biomaterials advances·2026

Same author

Work stressors, work-related quality of life, psychological capital, and innovative behavior in emergency and critical care nurses: a cross-sectional moderated mediation study.

Frontiers in psychology·2026

Same author

Tricellulin regulates the tight junctions and cytoskeleton of pancreatic acinar cells through the NF-κB pathway in hypertriglyceridemic acute pancreatitis.

Biomedical reports·2026

Same author

Anti-inflammatory sesquiterpenes and diterpenes from Tripterygium wilfordii Hook. f.

Fitoterapia·2026

Same author

Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.

Journal of nanobiotechnology·2026

Same author

Geometric and Electronic Engineering of Hydrogen Peroxide Production Electrocatalysts.

Nano-micro letters·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.

Hugo R Rosen¹, Scott J Weston, KyungAh Im

¹Integrated Program in Immunology and Hepatitis C Research Center, Division of Gastroenterology and Hepatology, University of Colorado, Denver, CO, USA. hugo.rosen@uchsc.edu

Hepatology (Baltimore, Md.)

|July 31, 2007

Summary

African Americans exhibit weaker Hepatitis C virus (HCV)-specific immunity compared to Caucasians. Pretreatment immune response significantly impacts the success of antiviral therapy for chronic HCV infection.

More Related Videos

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Related Experiment Videos

Last Updated: Jul 13, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Area of Science:

Immunology
Hepatology
Virology

Background:

Hepatitis C virus (HCV) infection is a major global cause of liver disease and cancer.
Racial disparities exist in HCV natural history and treatment outcomes, but underlying mechanisms are poorly understood.
Type 1 helper (Th1) immune responses are crucial for controlling viral infections.

Purpose of the Study:

To investigate racial differences in HCV-specific T cell immunity between Caucasian Americans (CAs) and African Americans (AAs).
To determine the association between HCV-specific immunity and sustained virologic response (SVR) to antiviral therapy.

Main Methods:

Used interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay to measure Th1 responses to HCV and cytomegalovirus (CMV) antigens.
Analyzed 187 CAs and 187 AAs with chronic genotype 1 HCV infection.
Correlated immune responses with human leukocyte antigen (HLA) class II alleles and treatment outcomes.

Main Results:

African Americans (AAs) demonstrated significantly lower Th1 responses to HCV core protein and combined antigens compared to Caucasian Americans (CAs).
Cytomegalovirus (CMV)-specific responses were comparable between racial groups.
Lower HCV-specific immunity in AAs persisted after adjusting for clinical factors and was not explained by HLA class II allele differences.
Pretreatment HCV-specific CD4+ T cell response was significantly associated with achieving SVR to pegylated IFN and ribavirin therapy (43% vs. 28% SVR).

Conclusions:

African Americans exhibit weaker Hepatitis C virus (HCV)-specific immunity compared to Caucasian Americans.
Pretreatment HCV-specific immunity is a significant predictor of successful response to combination antiviral therapy.